DOCSLIB.ORG

Adding Heparin to Aspirin Reduces the Incidence of Myocardial Infarction and Death in Patients with Unstable Angina a Meta-Analysis Allison Oler, MD; Mary A

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Adding Heparin to Aspirin Reduces the Incidence of Myocardial Infarction and Death in Patients with Unstable Angina a Meta-Analysis Allison Oler, MD; Mary A Adding Heparin to Aspirin Reduces the Incidence of Myocardial Infarction and Death in Patients With Unstable Angina A Meta-analysis Allison Oler, MD; Mary A. Whooley, MD; Jacqueline Oler, PhD; Deborah Grady, MD, MPH Objective.\p=m-\Toestimate the risk of myocardial infarction (MI) and death in pa- lows time for endogenous fibrinolysis to tients with unstable angina who are treated with aspirin plus heparin compared with occur. In theory, adding heparin to aspi¬ treated with alone. rin should reduce intracoronary obstruc¬ patients aspirin blood reduce Data Sources.\p=m-\Studieswere retrieved using MEDLINE, bibliographies, and tion, improve coronary flow, consultation with myocardial ischemia, and ultimately de¬ experts. crease cardiac and in that enrolled with unstable morbidity mortality Study Selection.\p=m-\Onlypublished trials patients an- patients with unstable angina.9 Several gina, randomized participants to aspirin plus heparin vs aspirin alone, and reported randomized clinical trials have demon¬ incidence of myocardial infarction or death were included in the meta-analysis. strated a trend toward reduced risk of Data Extraction.\p=m-\Patientoutcomes including MI or death, recurrent ischemic death or nonfatal myocardial infarction in pain, and major bleeding during randomized treatment; revascularization proce- patients with unstable angina treated with dures after randomization; and MI or death during the 2 to 12 weeks following ran- aspirin plus intravenous heparin com¬ domization were extracted by 2 authors, 1 of whom was blinded to the journal, in- pared with patients treated with aspirin stitution, and author of each study. alone.7·10"14 However, it has not been es¬ tablished that the combina¬ Data randomized trials were included. The overall summary definitively Synthesis.\p=m-\Six tion of is to relative risk of MI or death randomized treatment was 0.67 con- aspirin plus heparin superior (RR) during (95% alone. We a fidence interval in with unstable treated with aspirin performed meta-analy¬ [CI], 0.44-1.02) patients angina aspirin sis of published randomized trials to de¬ plus heparin compared with those treated with aspirin alone. The summary RRs for termine whether treatment with intra¬ in treated with with secondary endpoints patients aspirin plus heparin compared venous heparin and aspirin is more those treated with aspirin alone were 0.68 (95% CI, 0.40-1.17) for recurrent ische- effective than treatment with aspirin mic pain; 0.82 (95% CI, 0.56-1.20) for MI or death 2 to 12 weeks following random- alone in preventing MI or death in pa¬ ization; 1.03 (95% CI, 0.74-1.43) for revascularization; and 1.99 (95% CI, 0.52-7.65) tients with unstable angina. for major bleeding. We found no statistically significant heterogeneity among indi- vidual study findings. METHODS Conclusions.\p=m-\Ourfindings are consistent with a 33% reduction in risk of MI or Literature Review death in patients with unstable treated with aspirin plus heparin compared angina We performed a literature search us¬ with those treated with aspirin alone. The bulk of evidence suggests that most pa- ing the MEDLINE database (January tients with unstable angina should be treated with both heparin and aspirin. 1966 to September 1995) with the key¬ JAMA. 1996;276:811-815 words "aspirin," "heparin," and "unstable angina." The search was not restricted to UNSTABLE ANGINA, ranging from of patients admitted to the hospital with citations in the English-language litera¬ progressive angina to angina at rest, unstable angina progress to myocardial ture. In addition, a manual search was results from intracoronary plaque dis¬ infarction (MI) within 2 weeks of diag¬ done using reference lists from identified ruption causing increased stenosis and, nosis.2·3 One-year mortality of patients articles and consultation with experts. in some cases, intermittent thrombosis.1 with unstable angina ranges from 5% to Studies included in the meta-analysis Prospective studies have found that 12% 14% with approximately half of these met the following criteria: (1) a random¬ deaths occurring within 4 weeks of di¬ ized clinical trial; (2) eligible participants In patients with unstable an¬ were admitted to the hospital with the A. agnosis.4 From the Departments of Medicine (Drs Oler, reduces the risk of throm¬ of unstable or non-Q- Whooley, and Grady) and Epidemiology and Biostatis- gina, aspirin diagnosis angina tics (Dr Grady), University of California, San Francisco, bosis by inhibiting platelet aggregation wave myocardial infarction; (3) partici¬ School of Medicine; the General Internal Medicine and decreases the risk of cardiac death pants were assigned either to intrave¬ Section, San Francisco Veterans Affairs Medical Cen- or nonfatal MI by 30% to 51% 7 nous heparin and aspirin or to aspirin ter (Drs Whooley and Grady); and the Department of incidence of Quantitative Methods, Drexel University, Philadelphia, Heparin binds to antithrombin III and alone; and (4) the myocar¬ Pa (Dr J. Oler). induces a conformational change that re¬ dial infarction (prolonged chest pain as¬ Reprints: Deborah Grady, MD, MPH, General Inter- sults in inhibition ofthrombin.8 This sociated with waves or ST nal Medicine Section, San Francisco Veterans Affairs rapid Q persistent Medical Center, 111A1, 4150 Clement St, San Fran- inhibition of thrombin prevents propaga¬ changes on electrocardiogram and/or a cisco, CA 94121. tion of an established thrombus and al- 2-fold increase over baseline creatine Downloaded from www.jama.com at New York State Psychiatric Institute on August 3, 2009 kinase levels with elevated MB fractions) Table 1.—Characteristics of 6 Randomized Trials of Aspirin Plus Heparin vs Aspirin Alone to Prevent or death while on randomized treatment Myocardial Infarction and Death in Patients Admitted to the Hospital With Unstable Angina was reported. Clinical trials were in¬ Goal Partial cluded regardless of whether they in¬ Aspirin Thromboplastin Duration of Source d cluded a heparin placebo in the aspirin Blinding Dose, mg Time Heparin Therapy, et and 325 twice 1.5-2 X normal or the had been tak¬ Theroux al, 1988'° Participants daily only group patients investigators to admission. ing aspirin prior hospital RISC Group, 19907 None 75 daily Not stated Data Extraction Cohen et al, 1990" None 80/325 dally* Cohen et al, 1994" Participants 162.5 daily 2 x normal 3-4 Two of us and inde¬ (A.O. M.A.W.) et 150 1.5-2 x normal pendently reviewed each study that met Holdright al, 1994" Participants daily Gurfinkel et al, 1995" and 200 2 normal 5-7 the inclusion criteria. One of us ab¬ Participants daily investigators stracted data in an unblinded fashion; the other was blinded to journal, year of *Aspirin dose was 80 mg/d in the heparin plus aspirin group and 325 mg/d in the aspirin only group. publication, authors, and institution. We evaluated each study with regard to pa¬ tient selection, blinding, and adequacy measure, or estimated overall RR, was RESULTS of randomization, and recorded the dos¬ calculated using the DerSimonian and Study Selection age and duration of each treatment. Dis¬ Laird model which uses a random effects crepant findings between reviewers model to incorporate variance between An initial search using MEDLINE, ref¬ were settled by discussion. study findings in a weighted average of erence review, and expert consultation Heparin was given as a continuous in¬ rate ratios.18·19 Approximate 95% CIs were yielded 135 citations. Of these, 19 were fusion in 5 of 6 studies1044 with the rate obtained on the natural log transforma¬ randomized trials.7·9"14·22^3 Amongthese tri¬ adjusted to achieve a goal partial throm- tion scale and the limits reexpressed us¬ als, we found 8 that enrolled participants boplastin time (PTT) of 1.5 to 2 times ing the natural antilog transformation. A with unstable angina, randomized par¬ normal (Table 1). In the sixth study, hep¬ 2 statistic summing the squared devia¬ ticipants to aspirin or heparin plus aspi¬ arin was administered as intermittent in¬ tion ofeach ofthe study natural log trans¬ rin, and reported the risk of MI or death travenous boluses and a goal PTT was not formations ofthe OR from their weighted during randomized treatment.7·9"14·80 One stated.7 The duration of heparin therapy average was used to test whether a sum¬ of the 8 trials was excluded because we was 2 to 7 days in all studies. Aspirin was mary OR was appropriate for each end- could not determine whether all patients given orally in the doses shown in Table point. These calculations were substan¬ were treated with aspirin.30 Another was 1 and continued indefinitely. tiated using the log linear fits discussed excluded because only a portion of the Incidence of MI or death during ran¬ next, and obtained using BMDP statis¬ patients in the study received aspirin.9 domized treatment was abstracted as the tical software.20 Thus, 6 trials with a total of 1353 patients primary outcome. In addition, data were The primary endpoint in this meta- met all inclusion criteria for the meta- abstracted on incidence of recurrent is¬ analysis was MI or death while on ran¬ analysis.7·10"14 Characteristics of these tri¬ chemie pain (anginal chest pain with is¬ domized treatment. Relationships among als are shown in Table 1. chemie ST-T changes on electrocardio¬ the 3 dichotomous factors—myocardial All 6 trials excluded participants who gram) and major bleeding (bleeding infarction or death, treatment regimen, had evolving Q-wave MI on admission; requiring transfusion or fall in hemoglo¬ and study—were explored furtherby fit¬ coronary artery bypass grafting within bin by at least 20 g/L) during randomized ting a hierarchical log-linear model to the 12 months prior to admission; a contra¬ treatment. We also abstracted data on cell counts.21 This approach models the indication to aspirin or anticoagulation; MI or death between discontinuation of natural log cell frequencies as linear com¬ or had already been anticoagulated at ad¬ randomized treatment and 12 weeks fol¬ binations of main effects, and second-or¬ mission.
Load more

Recommended publications
  • Enoxaparin Sodium Solution for Injection, Manufacturer's Standard
    PRODUCT MONOGRAPH INCLUDING PATIENT MEDICATION INFORMATION PrLOVENOX® Enoxaparin sodium solution for injection 30 mg in 0.3 mL solution (100 mg/mL), pre-filled syringes for subcutaneous or intravenous injection 40 mg in 0.4 mL solution (100 mg/mL), pre-filled syringes for subcutaneous or intravenous injection 60 mg in 0.6 mL solution (100 mg/mL), pre-filled syringes for subcutaneous or intravenous injection 80 mg in 0.8 mL solution (100 mg/mL), pre-filled syringes for subcutaneous or intravenous injection 100 mg in 1 mL solution (100 mg/mL), pre-filled syringes for subcutaneous or intravenous injection 300 mg in 3 mL solution (100 mg/mL), multidose vials for subcutaneous or intravenous injection PrLOVENOX® HP Enoxaparin sodium (High Potency) solution for injection 120 mg in 0.8 mL solution (150 mg/mL), pre-filled syringes for subcutaneous or intravenous injection 150 mg in 1 mL solution (150 mg/mL), pre-filled syringes for subcutaneous or intravenous injection Manufacturer’s standard Anticoagulant/Antithrombotic Agent ATC Code: B01AB05 Product Monograph – LOVENOX (enoxaparin) Page 1 of 113 sanofi-aventis Canada Inc. Date of Initial Approval: 2905 Place Louis-R.-Renaud February 9, 1993 Laval, Quebec H7V 0A3 Date of Revision September 7, 2021 Submission Control Number: 252514 s-a version 15.0 dated September 7, 2021 Product Monograph – LOVENOX (enoxaparin) Page 2 of 113 TABLE OF CONTENTS Sections or subsections that are not applicable at the time of authorization are not listed. TABLE OF CONTENTS ..............................................................................................................
    [Show full text]
  • Rtpa) for the Treatment of Hepatic Veno-Occlusive Disease (VOD
    Bone Marrow Transplantation, (1999) 23, 803–807 1999 Stockton Press All rights reserved 0268–3369/99 $12.00 http://www.stockton-press.co.uk/bmt Recombinant tissue plasminogen activator (rtPA) for the treatment of hepatic veno-occlusive disease (VOD) S Kulkarni1, M Rodriguez2, A Lafuente2, P Mateos2, J Mehta1, S Singhal1, R Saso3, D Tait4, JG Treleaven3 and RL Powles1 Departments of 1Medical Oncology, 3Haematology and 4Radiotherapy, Royal Marsden NHS Trust, Sutton, Surrey, UK; and 2Haematology Department, Hospital La Paz, Madrid, Spain Summary: clinical syndrome characterized by hyperbilirubinemia, hepatomegaly and fluid retention,2,3 and results from dam- Seventeen patients who developed hepatic veno-occlus- age to structures in zone 3 of the liver acinus.4 In patients ive disease (VOD) following hematopoietic stem cell who have undergone hematopoietic stem cell transplan- transplantation were treated with recombinant tissue tation, chemoradiotherapy-induced endothelial cell damage plasminogen activator (rtPA) with or without heparin. is likely to be responsible for the pathogenesis of vessel rtPA was started a median of 13 days post transplant obstruction.5 (range 4–35). All patients received rtPA at a dose of 10 Treatment of established VOD has primarily been sup- mg/day as a starting dose, and 12 patients also received portive and any specific measures have resulted in little heparin (1500 U bolus; then 100 U/kg/day as a continu- impact on outcome. Based on the available evidence for ous i.v. infusion). The median number of days of rtPA involvement of hemostatic mechanisms and cytokines in therapy was 2.5 (1–12). The median total serum biliru- the pathogenesis of VOD,6–8 anti-thrombotic and anti-cyto- bin level was 116 mmol/l (range 63–194) at the begin- kine agents have been assessed for their role in treatment.
    [Show full text]
  • Transition of Anticoagulants 2019
    Transition of Anticoagulants 2019 Van Hellerslia, PharmD, BCPS, CACP, Brand Generic Clinical Assistant Professor of Pharmacy Practice, Angiomax bivalirudin Temple University School of Pharmacy, Philadelphia, PA Arixtra fondaparinux Bevyxxa betrixaban Pallav Mehta, MD, Assistant Professor of Medicine, Coumadin warfarin Division of Hematology/Oncology, Eliquis apixaban MD Anderson Cancer Center at Cooper, Camden, NJ Fragmin dalteparin Lovenox enoxaparin Reviewer: Kelly Rudd, PharmD, BCPS, CACP, Pradaxa dabigatran Clinical Specialist, Anticoagulation, Bassett Medical Center, Savaysa edoxaban Cooperstown, NY Xarelto rivaroxaban From To Action Apixaban Argatroban/ Wait 12 hours after last dose of apixaban to initiate parenteral anticoagulant. In cases of Bivalirudin/ high bleeding risk, consider omitting initial bolus when transitioning to heparin infusion. Enoxaparin/ Dalteparin/ Fondaparinux/ Heparin Apixaban Warfarin When going from apixaban to warfarin, consider the use of parenteral anticoagulation as a bridge (eg, start heparin infusion or therapeutic enoxaparin AND warfarin 12 hours after last dose of apixaban and discontinue parenteral anticoagulant when INR is therapeutic). Apixaban affects INR so that initial INR measurements during the transition may not be useful for determining the appropriate dose of warfarin. Apixaban Betrixaban, Wait 12 hours from last dose of apixaban to initiate betrixaban, dabigatran, edoxaban, or Dabigatran, rivaroxaban. Edoxaban, or Rivaroxaban Argatroban Apixaban, Start apixaban, betrixaban, dabigatran,
    [Show full text]
  • (Dipotassium Salt) and Heparin on the Estimation of Packed Cell Volume
    J Clin Pathol: first published as 10.1136/jcp.19.2.196 on 1 March 1966. Downloaded from J. clin. Path. (1966), 19, 196 Effect of ethylene-diamine-tetra-acetic acid (dipotassium salt) and heparin on the estimation of packed cell volume C. A. PENNOCK AND K. W. JONES From the Department of Haematology, Gibson Laboratories, Radcliffe Infirmary, Oxford SYNOPSIS The effect of varying concentrations of ethylene-diamine-tetra-acetic acid (E.D.T.A.) (dipotassium salt) and heparin on the estimation of packed cell volume has been studied using a microhaematocrit method. Varying concentrations of E.D.T.A. can produce serious errors in estimation of packed cell volume (P.C.V.) and reliable results are only obtained within the range of 1 to 2 mg./ml. Heparin is a more suitable anticoagulant for this investigation as varying the con- centration has little effect. Storage with either anticoagulant at suitable concentrations for 24 hours at room temperature has little influence on the results. The estimation ofthe packed cell volume (P.C.V.) is bottles are often returned to this laboratory contain- regarded as a reliable investigation in the diagnosis ing less than the recommended amount of blood.copyright. of anaemia, and errors in the estimation of mean Ethylene-diamine-tetra-acetic acid is known to corpuscular haemoglobin concentration (M.C.H.C.) cause distortion and shrinkage of red cells and are thought to be due more often to errors in the to affect the estimation of P.C.V. by conventional estimation of haemoglobin than of the P.C.V.
    [Show full text]
  • Direct Versus Indirect Thrombin Inhibition in Percutaneous Coronary Intervention
    Direct Versus Indirect Thrombin Inhibition in Percutaneous Coronary Intervention Jonathan D. Marmur, MD, FACC Heparin rally occurring but slow thrombin inhibitor. The heparin:AT interaction produces conformational Heparin has been used to prevent intravascular changes in AT and accelerates its inhibition of throm- thrombosis and clotting on the surface of equipment bin, factor Xa, and factor IXa.10 used during percutaneous coronary interventions (PCI) Heparin catalysis of factor Xa inhibition does not since Andreas Gruentzig performed the first require bridging between factor Xa and AT. Since almost angioplasty.1 In fact, the development of coronary all the heparin chains are at least 18 units long, heparin angioplasty and of coronary artery bypass surgery would has equivalent inhibitory activity against thrombin and probably not have been possible without heparin. How- factor Xa.3 However, when thrombin is bound to fibrin, ever, with the availability of low molecular weight the heparin:AT complex is less able to access and inhibit heparin (LMWH) and the approval of bivalirudin, a thrombin.9 Furthermore, with respect to anti Xa activity, direct thrombin inhibitor for use during PCI, the ques- the heparin:AT complex is unable to inhibit factor Xa tion is more and more frequently asked whether heparin bound to the surface of activated platelets.11 should be replaced in PCI. The purpose of this paper is to critically review the evidence for the use of heparins Pharmacokinetics/pharmacodynamics. Heparin (indirect thrombin inhibitors) and direct thrombin must be given by injection since it is not absorbed when inhibitors during PCI. administered orally.10 Heparin is cleared via a biphasic process combining rapid saturable and slower first- Structure and mechanism of action of heparin.
    [Show full text]
  • Public Assessment Report
    PUBLIC ASSESSMENT REPORT Decentralised Procedure Fraxiparine 0.3 2,850 I.U. anti-Xa/ 0.3 ml; Fraxiparine 0.4 3,800 I.U. anti-Xa/ 0.4 ml; Fraxiparine 0.6 5,700 I.U. anti-Xa/ 0.6 ml; Fraxiparine 0.8 7,600 I.U. anti-Xa/ 0.8 ml Procedure Number: DE/H/4762/002-005/DC Fraxodi 19000 UL / ml; 0.6 ml Fraxodi 19000 UL / ml; 0.8 ml Fraxodi 19000 UL / ml; 1.0 ml Procedure Number: DE/H/4763/001-003/DC Fraxiparine Multi 9,500 anti-Xa IU/ 1.0 ml Fraxiparine Multi 9,500 anti-Xa IU/ 1.0 ml Procedure Number: DE/H/4770/001-002/DC Active Substance: Nadroparin-Calcium Dosage Form: Solution for injection Marketing Authorisation Holder in the RMS, Germany: Aspen Pharma Trading Limited Publication: 19.11.2018 TABLE OF CONTENTS I. RECOMMENDATION ................................................................................................................ 4 II. EXECUTIVE SUMMARY ....................................................................................................... 4 II.1 Problem statement ..................................................................................................................... 4 II.2 About the product ..................................................................................................................... 4 II.3 General comments on the submitted dossier .......................................................................... 4 II.4 General comments on compliance with GMP, GLP, GCP and agreed ethical principles. 5 III. SCIENTIFIC OVERVIEW AND DISCUSSION ..................................................................
    [Show full text]
  • Elective Surgery and Invasive Procedures in Patients Taking
    Volume 10, No. 5 January 2020 This Medicines Information Leaflet is produced locally to optimise the use of medicines by encouraging prescribing that is safe, clinically appropriate and cost-effective to the NHS. The management of patients who are receiving oral therapy if they are regarded as at high risk of anticoagulation with warfarin or a Direct Oral thrombosis (see table 1). The dose of dalteparin Anticoagulant (DOAC e.g. dabigatran, rivaroxaban, recommended for bridging is outlined in table 2. apixaban, edoxaban) who require surgery or are All patients who do not require bridging with full undergoing a procedure depends on the underlying treatment dose heparin peri-operatively should be thrombotic risk, the intended surgical intervention, risk assessed and given prophylactic dose LMWH as and the risk of bleeding associated with it. This MIL appropriate. covers the management of patients on warfarin or a DOAC undergoing elective procedures, grouped into Table 1: Consider bridging with full treatment dose three categories: major surgery (excluding vascular heparin in patients who stop warfarin if thrombotic surgery), minor surgery and endoscopy. risk is high Note: Patients within 3 months of acute venous Consider bridging with full treatment dose thromboembolism (VTE) are at high risk of recurrent heparin in: VTE if anticoagulation is stopped; it is estimated that VTE Patients with a VTE within previous 3 cessation of anticoagulation in the first month after months. an acute VTE is associated with a 40% one-month risk of recurrent VTE, and 10% for the subsequent Very high risk patients such as patients with two months. Therefore, wherever possible elective a previous VTE whilst on therapeutic surgery should be delayed until 3 months after an anticoagulation who now have a target INR acute VTE.
    [Show full text]
  • Cleveland Clinic Anticoagulation Management Program (C-Camp)
    CLEVELAND CLINIC ANTICOAGULATION MANAGEMENT PROGRAM (C-CAMP) 1 Table of Contents I. EXECUTIVE SUMMARY ......................................................................................................................................... 6 II. VENOUS THROMBOEMBOLISM RISK ASSESSMENT AND PROPHYLAXIS ............................................. 9 III. RECOMMENDED PROPHYLAXIS OPTIONS FOR THE PREVENTION OF VENOUS THROMBOEMBOLISM. ........................................................................................................................................ 10 IIIA. RECOMMENDED PROPHYLAXIS OPTIONS FOR THE PREVENTION OF VENOUS THROMBOEMBOLISM BASED ON RISK FACTOR ASSESSMENT ............................................................. 12 A) UNFRACTIONATED HEPARIN (UFH) ................................................................................................................... 14 B) LOW MOLECULAR WEIGHT HEPARIN (LMWH) ENOXAPARIN (LOVENOX®) .............................................. 14 C) FONDAPARINUX/ (ARIXTRA®) …………………………………………………………………………..……16 D) RIVAROXABAN (XARELTO®) .......................................................................................................................... 16 E) DESIRUDIN (IPRIVASK®)………………………………………………………………………………..…….17 F) WARFARIN/COUMADIN®) ............................................................................................................................... 16 G) ASPIRIN……………………………………………………………………………………………………..……18 H) INTERMITTENT PNEUMATIC COMPRESSION DEVICES .....................................................................................
    [Show full text]
  • Enoxaparin Updated November 2016
    Enoxaparin Updated November 2016 Enoxaparin is a low-molecular weight heparin (LMWH). Because of its lower protein-binding compared to unfractionated heparin (UFH), enoxaparin has more predictable pharmacokinetics and less need for therapeutic monitoring. Enoxaparin is frequently used as prophylaxis for deep venous thrombosis (DVT) in critically ill human patients. The ideal prophylactic regimen in critical care patients is still unclear and remains highly investigated. Individual patient factors (such as BMI and renal function) alter drug metabolism and, therefore, serum drug level monitoring to achieve a target anti-Xa factor blood level is ideal in higher risk patients. The availability of drug monitoring is poor and impractical in most veterinary settings. Thus recommendations for dose, route, and interval of administration in veterinary patients are extrapolated from those used in human patients. The ideal application, dosing guideline, and safety in veterinary patients remain unknown. Mechanism of Action: Heparin and LMW-heparins prevent clot formation by binding antithrombin. The heparin-antithrombin complex can then bind to and inactivate either thrombin (Factor II) or activated-Factor Xa. Low-molecular weight heparin will only bind and inactivate activated Factor Xa. Derivation and Metabolism: Derived from heparin to yield fragments one third the size of heparin. Mean LMWH size: 4500-5000 Da Metabolism: Hepatic metabolism via breakdown to less biologically active molecules. Approximately 10% of the Copyright: PolyMedix active drug is renally excreted. Maximum anti-Xa and anti-thrombin activity occurs 3-5 hours after administration. Steady state achieved after 24 hours of therapy Elimination half-life 4.5 hours (single dose) or 7 hours (repeated doses) Benefits of LMWHs: Lower binding properties than unfractionated heparin (UFH).
    [Show full text]
  • Transition of Anticoagulants 2016
    Transition of Anticoagulants 2016 Van Hellerslia, PharmD, BCPS, CACP, Clinical Assistant Professor of Pharmacy Practice, Brand Generic Temple University School of Pharmacy, Philadelphia, PA Angiomax bivalirudin Arixtra fondaparinux Pallav Mehta, MD, Assistant Professor of Medicine, Coumadin warfarin Division of Hematology/Oncology, Eliquis apixaban MD Anderson Cancer Center at Cooper Fragmin dalteparin Lovenox enoxaparin Reviewer: Kelly Rudd, PharmD, BCPS, CACP, Clinical Specialist, Anticoagulation, Pradaxa dabigatran Savaysa edoxaban Bassett Medical Center, Cooperstown, New York Xarelto rivaroxaban From To Action Apixaban Argatroban/ Wait 12 hours after last dose of apixaban to initiate parenteral anticoagulant. In cases of Bivalirudin/ high bleeding risk, consider omitting initial bolus when transitioning to heparin infusion. Enoxaparin/ Dalteparin/ Fondaparinux/ Heparin Apixaban Warfarin When going from apixaban to warfarin, consider the use of parenteral anticoagulation as a bridge (eg, start heparin infusion/enoxaparin and warfarin 12 hours after last dose of apixaban and discontinue parenteral anticoagulant when INR is therapeutic ≥2). Apixaban Dabigatran, Wait 12 hours from last dose of apixaban to initiate dabigatran, edoxaban, or rivaroxaban. Edoxaban, or Rivaroxaban Argatroban Apixaban, Start apixaban, dabigatran, edoxaban, or rivaroxaban within 2 hours of stopping argatroban. Dabigatran, Edoxaban, or Rivaroxaban Argatroban Enoxaparin/ If no hepatic insufficiency, start parenteral anticoagulant within 2 hours of stopping Dalteparin/ argatroban. If there is hepatic insufficiency, start parenteral anticoagulant after 2-4 hours of Fondaparinux/ stopping argatroban. Heparin *The use of enoxaparin/dalteparin/heparin assumes the patient does not have heparin allergy or heparin-induced thrombocytopenia. Argatroban Warfarin Argatroban must be continued when warfarin is initiated and co-administration should continue for at least 5 days. Argatroban elevates the INR.
    [Show full text]
  • The Pharmacodynamic Effect of ELIQUIS Can Be Expected to Persist for at Least 24 Hours After the Last Dose, Ie, for About Two Drug Half Lives
    Dosing Guide for All ELIQUIS Indications Find out more at hcp.eliquis.com Please see full Prescribing Information including Boxed WARNINGS and Medication Guide or visit ELIQUIS.com. ELIQUIS® (apixaban) INDICATIONS Approved for 6 indications to reduce the risk of stroke and systemic embolism in patients with nonvalvular atrial fibrillation (NVAF) for the treatment of deep vein thrombosis (DVT) for the treatment of pulmonary embolism (PE) to reduce the risk of recurrent DVT and PE following initial therapy for the prophylaxis of DVT, which may lead to PE, in patients who have undergone hip replacement surgery for the prophylaxis of DVT, which may lead to PE, in patients who have undergone knee replacement surgery SELECTED IMPORTANT SAFETY INFORMATION WARNING: (A) PREMATURE DISCONTINUATION OF ELIQUIS INCREASES THE RISK OF THROMBOTIC EVENTS, (B) SPINAL/EPIDURAL HEMATOMA (A) Premature discontinuation of any oral anticoagulant, including ELIQUIS, increases the risk of thrombotic events. If anticoagulation with ELIQUIS is discontinued for a reason other than pathological bleeding or completion of a course of therapy, consider coverage with another anticoagulant. (B) Epidural or spinal hematomas may occur in patients treated with ELIQUIS who are receiving neuraxial anesthesia or undergoing spinal puncture. These hematomas may result in long-term or permanent paralysis. Consider these risks when scheduling patients for spinal procedures. Factors that can increase the risk of developing epidural or spinal hematomas in these patients include: • use of indwelling epidural catheters • concomitant use of other drugs that affect hemostasis, such as nonsteroidal anti-inflammatory drugs (NSAIDs), platelet inhibitors, other anticoagulants • a history of traumatic or repeated epidural or spinal punctures • a history of spinal deformity or spinal surgery • optimal timing between the administration of ELIQUIS and neuraxial procedures is not known Monitor patients frequently for signs and symptoms of neurological impairment.
    [Show full text]
  • Expert John L
    Ask the expert John L. Petrini, Antithrombotic agents during endoscopy MD, FASGE 1. Q: Do you routinely discontinue warfarin in patients with chronic atrial fibrillation without valvular heart disease or prior embolic events prior to: Ask the expert features A. Routine screening colonoscopy? questions submitted by B. Colonoscopy for a positive fecal occult blood test? C. Endoscopy for iron deficiency anemia? members, with answers D. Colonoscopy for prior adenomatous polyp(s)? provided by ASGE A: The decision to stop anticoagulation depends on the perceived risk of a thromboembolic event. If the risk is physician experts. ASGE’s high (e.g., elderly patient, chronic atrial fibrillation, valvular heart disease or prior thromboembolic events), the morbidity and mortality associated with interrupting or modifying anticoagulation is substantial, which, in Publications Committee my opinion, is unacceptable. Therefore, in those patients, I do not recommend stopping anticoagulation before identifies authors and routine screening colonoscopy (A). topics for the column. In fact, I do not recommend stopping anticoagulation for colonoscopy in patients with any of the above In this issue, ASGE indications. The decision to modify or stop anticoagulation for patients who have positive fecal occult blood 2008-09 Past President, tests or iron deficiency anemia is left to the cardiologist or primary care physician. For patients undergoing surveillance colonoscopy for prior adenomatous polyps, I do not interrupt anticoagulation for high-risk patients John L. Petrini, MD, and advise them of the slightly increased risk of bleeding associated with removing polyps while on FASGE, responds an anticoagulant. to questions on antithrombotic agents 2. Q: What are your thoughts on starting aspirin and/or clopidogrel (Plavix) after a polypectomy for a 1 cm or larger pedunculated polyp? during endoscopy.
    [Show full text]